imatinib mesylate has been researched along with Demyelinative Myelitis in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cortes, J; Daver, NG; Jabbour, EJ; Kadia, TM; Kamiya-Matsuoka, C; Kantarjian, H; Konopleva, M; Mehta, RS; Naqvi, K; Rafei, H; Sinicrope, KD | 1 |
1 other study(ies) available for imatinib mesylate and Demyelinative Myelitis
| Article | Year |
|---|---|
Neurotoxic events associated with BCR-ABL1 tyrosine kinase inhibitors: a case series.
Topics: Aged; Dasatinib; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Intervertebral Disc Degeneration; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Myelitis, Transverse; Optic Neuritis; Protein Kinase Inhibitors | 2019 |